[
    {
        "title": "Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis - Yahoo Finance",
        "description": "Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis  Yahoo Finance",
        "published date": "Tue, 10 Oct 2023 07:00:00 GMT",
        "url": "https://consent.google.com/m?continue=https://news.google.com/rss/articles/CBMiS2h0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9ub3ZvLW5vcmRpc2stc3RvcC1vbmNlLXdlZWtseS0yMDM3MDA3NTIuaHRtbNIBU2h0dHBzOi8vZmluYW5jZS55YWhvby5jb20vYW1waHRtbC9uZXdzL25vdm8tbm9yZGlzay1zdG9wLW9uY2Utd2Vla2x5LTIwMzcwMDc1Mi5odG1s?oc%3D5&gl=IT&m=0&pc=n&cm=2&hl=en-US&src=1"
    }
]